ArticleFrontiers in cellular and infection microbiology2026
The serum C1q-to-CRP ratio performs well for diagnosing periprosthetic joint infection in revision arthroplasty.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Periprosthetic joint infection (PJI) is a severe complication after total joint arthroplasty (TJA). Conventional biomarkers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) often show limited accuracy in complex cases. Complement C1q is a critical initiator of the classical complement pathway, but its diagnostic value in PJI has not been investigated. Methods: We retrospectively analyzed 168 patients undergoing revision arthroplasty (71 PJI and 97 aseptic loosening [AL]). Preoperative serum levels of C1q, CRP, ESR, and fibrinogen (FIB) were measured. Diagnostic models including the C1q-to-CRP ratio (CCR), ESR-to-C1q ratio (ECR), and FIB-to-C1q ratio (FCR) were calculated. ROC curve analysis and DeLong's test were used to assess diagnostic performance. Decision curve analysis (DCA) was conducted to assess the clinical net benefit of the CCR model. An exploratory stratified analysis was further performed in the diabetic subgroup (n=48). Results: Serum C1q levels were significantly higher in the PJI group compared to the AL group (236.00 vs. 180.00 mg/L, P < 0.001). C1q positively correlated with CRP (rho = 0.62), ESR (rho = 0.33), and FIB (rho = 0.31). The CCR model demonstrated the highest diagnostic accuracy with an AUC of 0.949, which was significantly superior to CRP alone (AUC = 0.931, P = 0.022). At a cut-off of 0.03, CCR yielded a sensitivity of 95.77% and a negative predictive value of 96.20%. In the diabetic subgroup, CCR remained effective with an AUC of 0.928. Conclusion: Serum C1q is a reliable novel biomarker for PJI. The CCR model demonstrates promising research prospects and can serve as a reliable tool for clinical decision-making in the diagnosis and treatment of PJI, including for diabetic patients. DCA showed that CCR provided superior net clinical benefit across most threshold probabilities in both the overall and diabetic cohorts, supporting its potential clinical utility in PJI diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.